BioCentury
ARTICLE | Company News

ICER finds opioid use disorder treatments not cost-effective

September 14, 2018 5:28 PM UTC

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines.

The institute compared the clinical effectiveness and value of three buprenorphine products and a naltrexone product against drugs such as Suboxone buprenorphine/naltrexone sublingual film and methadone using a broad set of outcomes, including short- and long-term abstinence from opioid use and opioid withdrawal syndrome. The MATs included two recently marketed buprenorphine products -- once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and implant Probuphine from Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) -- as well as Braeburn's extended-release injection CAM2038, which is under FDA review, and injectable Vivitrol naltrexone from Alkermes plc (NASDAQ:ALKS) (see "ICER to Consider Broad Outcomes for Buprenorphines"). ...